Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Company Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Key Stats

• Today's Range: $140.54 to $146.23
• 50-Day Range: $112.93 to $153.43
• 52-Week Range: $85.29 to $161.00
• Volume: 411,702 shs
• Average Volume: 451,002 shs
• Market Capitalization: $8.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $195.00
• Consensus Rating: Moderate Buy

Ascendis Pharma A/S Stock Analysis - MarketRank™

Ascendis Pharma A/S scored higher than 73% of companies evaluated by MarketBeat, and ranked 295th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ascendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ascendis Pharma A/S has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($7.15) to ($3.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ascendis Pharma A/S is -14.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ascendis Pharma A/S is -14.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.74% of the outstanding shares of Ascendis Pharma A/S have been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently decreased by 5.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascendis Pharma A/S does not currently pay a dividend.

Dividend Growth

Ascendis Pharma A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.74% of the outstanding shares of Ascendis Pharma A/S have been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently decreased by 5.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.90

News Sentiment

Ascendis Pharma A/S has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Ascendis Pharma A/S this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

ASND Stock Analysis - Frequently Asked Questions

How have ASND shares performed this year?

Ascendis Pharma A/S's stock was trading at $125.95 on January 1st, 2024. Since then, ASND stock has increased by 11.9% and is now trading at $140.95.
View the best growth stocks for 2024 here.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings data on Tuesday, September, 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by $0.51. The biotechnology company earned $38.75 million during the quarter, compared to analysts' expectations of $94.74 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative trailing twelve-month return on equity of 16,574.15%.

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD) and Incyte (INCY).

Company Calendar

• Last Earnings: 9/03/2024
• Today: 10/04/2024
• Next Earnings (Estimated): 11/05/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASND
• CUSIP: N/A
• CIK: 1612042
• Web: www.ascendispharma.com
• Phone: (457) 022-2244
• Fax: 45-3694-4010
• Employees: 640
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $195.00
• High Stock Price Target: $289.00
• Low Stock Price Target: $140.00
• Potential Upside/Downside: +38.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-521,070,000.00
• Net Margins: -154.18%
• Pretax Margin: -151.74%
• Return on Equity: -16,574.15%
• Return on Assets: -59.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.44

Sales & Book Value

• Annual Sales: $317.63 million
• Price / Sales: 25.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.73) per share
• Price / Book: -51.63

Miscellaneous

• Outstanding Shares: 58,231,000
• Free Float: 34,939,000
• Market Cap: $8.21 billion
• Optionable: Optionable
• Beta: 0.63